Pharma BD Deal Intelligence

AstraZeneca PLC / MedImmune Inc.

2007 · Acquisition/Merger · $15.6B · Complete

Announcement Sentiment

Positive

Outcome Score

Worked — the deal delivered on its rationale.

AstraZeneca acquired MedImmune for approximately $15.6 billion ($58 per share in cash), gaining a leading biologics and vaccines platform including blockbuster Synagis, FluMist, and a 45-project pipeline to transform AstraZeneca into an integrated biologics company.

Key facts

Announced Apr 23, 2007
Closed Jun 19, 2007
Deal value $15.6B
Deal type Acquisition/Merger
Therapeutic area Infectious Disease, Oncology, Respiratory, Vaccines
Indications RSV Prevention (Infants), Influenza, Respiratory Infections
Key assets Synagis (palivizumab), FluMist, Numax (motavizumab), 45-project biologics pipeline, Biologics manufacturing platform
Mechanism Monoclonal antibody (RSV F protein), Live attenuated influenza vaccine, Enhanced monoclonal antibody (RSV)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals